Cedrik Britten
Chief Medical Officer Immatics
Seminars
Tuesday 19th May 2026
Delivering Transformational Benefit with TCR-Based Therapies for PRAME Positive Cancers
10:30 am
- Demonstrating first-generation autologous TCR therapy Anzu-Cel achieving 50-60% durable responses in melanoma
- Advancing second-generation efficacy enhanced PRAME TCRs into ovarian and endometrial cancers and the prospect of tissue agnostic expansion
- Bispecific TCR approaches to maximize clinical impact while addressing development and scalability challenges
Tuesday 19th May 2026
C-Level Fireside Chat: Reflecting on Lessons from TCR Therapies to Drive Next-Generation Strategies
9:00 am
- Identifying pivotal learnings that can sharpen development strategies and accelerate stronger clinical outcomes
- Framing actionable insights that translate early proof-of-concept gains into durable, real-world clinical impact
- Exploring critical knowledge gaps and defining high-value priorities that can shape the next-generation of TCR innovations
